Incidence of Human Immunodeficiency Virus-1 (HIV-1) Infection in HIV-1 Uninfected High Risk Men Who Have Sex With Men

HIV Infections Clinical Trial

Official title:

A Cohort Study to Determine the Incidence of HIV-1 Infection in HIV-1 Uninfected High Risk Participants Who Are Male Sex at Birth and Have Sex With Men

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03310515
• Other study ID #: 206897
• Status: Completed
• Start date: August 31, 2017
• Est. completion date: December 31, 2018

Study information

• Verified date: March 2020
• Source: ViiV Healthcare
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Studies to assess the effectiveness of interventions to prevent HIV infection depend upon robust estimates of Baseline HIV incidence rates. The changing landscape of high-risk populations, as well as the evolution of biomedical pre-exposure prophylaxis (PrEP) interventions, requires a contemporary evaluation of HIV incidence as well as demographic, behavioral and other subject factors which may impact HIV incidence. This is a prospective cohort study to measure HIV-1 seroincidence in a study population of HIV-1 uninfected Chinese men who have sex with men (MSM) and transgender women (TGW) who are at high-risk of HIV infection. Approximately 550 subjects who are male sex at birth and have sex with men shall enter the study, which will allow for a 10% drop out rate to maintain 500 subjects at the conclusion of the cohort. This is a single arm cohort study to determine HIV-1 seroincidence rates in high risk MSM and TGW when combined with a comprehensive prevention package including HIV and safe sex counseling, provision of condoms and water-based lubricant, and sexually transmitted infection (STI) screening and referral for treatment. It will be determined what proportion of high-risk MSM and TGW who are given a comprehensive HIV-1 prevention package will acquire HIV-1 infection.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 578
• Est. completion date: December 31, 2018
• Est. primary completion date: December 31, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subjects are Chinese MSM and/or TGW and must be 18 years or older at the time of screening.

• Subjects of male sex at birth and who have sex with men, who in the 6 months prior to screening report one or more of the following risk criteria:

• Unprotected (condomless) receptive anal intercourse with one or more partners.

• More than five partners in the 6 months prior to enrolment (regardless of condom use and HIV serostatus, as reported by the enrolee).

• Reported STI with syphilis, gonorrhea, chlamydia, chancroid, or lymphogranuloma venereum.

Subjects in a monogamous relationship with an HIV-1 seronegative partner or a virologically-suppressed HIV-1 + partner for >1 year are not eligible for participation.

• Males, agree to appropriate use of contraceptive measures during heterosexual intercourse.

• Subjects who have non reactive fourth generation HIV test and undetectable HIV-1 RNA at screening.

• Capable of giving signed informed consent.

Exclusion Criteria:

• Subjects with known moderate to severe hepatic impairment as per liver function test criteria outlined below.

• Subject who, in the investigator's judgment, poses a significant suicide risk.

• The Subject has a tattoo or other dermatological condition overlying the gluteus region.

• Clinically significant cardiovascular disease, as defined by history/evidence of congestive heart failure, symptomatic arrhythmia, angina/ischemia, coronary artery bypass grafting (CABG) surgery or percutaneous transluminal coronary angioplasty (PTCA) or any clinically significant cardiac disease.

• Use of PrEP or post exposure prophylaxis (PEP) within the last 30 days prior to screening.

• Current use or anticipated need for use high dose aspirin or other anticoagulants including antiplatelet medications that would interfere with the ability to receive intramuscular (IM) injections.

• Exposure to an experimental drug and/or experimental vaccine within 28 days or 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to the screening.

• Anti-tuberculosis therapy.

• Alcohol use that in the judgment of the investigator would interfere with the subject's ability to complete study procedures.

• Active injection drug use that in the judgment of the investigator would interfere with the subject's ability to complete study procedures.

• Any medical condition, including psychiatric conditions, that in the judgment of the investigator would interfere with the subject's ability to complete study procedures.

• A reactive HIV test at screening.

• A positive Hepatitis B surface antigen.

• A positive Hepatitis C antibody with an HCV viral ribose nucleic acid (RNA) above the lower limit of detection.

• Any of the following laboratory values at screening:

• Hemoglobin (Hgb) <11 gram per deciliter (g/dL).

• Absolute neutrophil count <750 cells per cubic millimeter (cells/mm^3).

• Platelet count <100,000 cells/mm^3.

• Presence of a coagulopathy defined by an international normalized ratio (INR)>1.5 or a partial thromboplastin time (PTT)>45 seconds.

• Creatinine clearance <60 milliliter per minute (mL/min) using the Cockroft-Gault equation.

• Aspartate aminotransferase (AST) >1.5 times upper limit of normal (ULN).

• Direct Bilirubin >2.0 milligram per deciliter (mg/dL).

• Co-enrolment in any other HIV interventional studies.

Related Conditions & MeSH terms

• Acquired Immunodeficiency Syndrome
• Communicable Diseases
• HIV Infections
• Immunologic Deficiency Syndromes
• Infection
• Infection, Human Immunodeficiency Virus

Intervention

Behavioral:
• Risk reduction counseling
Subjects will receive comprehensive prevention package including HIV and safe sex counseling, provision of condoms and water-based lubricant, and STI screening and referral for treatment.

Other:
• Social harm interview
Information regarding social harms (loss of privacy, stigmatization, interference with gainful employment, and coercion) will be solicited during bi-monthly study visits after enrollment in the study and will be recorded. Subjects who report social harms will be referred to speak with a social worker and/or a study counselor.
• Computer-Assisted Self Interviewing technique
Demographic, behavioral, and psychosocial factors associated with HIV acquisition will be assessed by CASI.

Locations

Country	Name	City	State
China	GSK Investigational Site	Beijing
China	GSK Investigational Site	Beijing
China	GSK Investigational Site	Changsha
China	GSK Investigational Site	Chengdu	Sichuan
China	GSK Investigational Site	Guangzhou	Guangdong
China	GSK Investigational Site	Hangzhou	Zhejiang
China	GSK Investigational Site	Shanghai
China	GSK Investigational Site	Shenyang	Liaoning
China	GSK Investigational Site	Shenzhen

Sponsors (1)

Lead Sponsor	Collaborator
ViiV Healthcare

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	HIV-1 seroincidence rate in a cohort of high-risk MSM and TGW	Incidence of HIV-1 infection in subject's post-study entry will be assessed by determining number of subjects who become infected with HIV-1 post-screening and after study entry including Day 1 and subsequent observation visits. Confirmatory HIV serology test will be performed at seroconversion visit.	Baseline, Day 1, Weeks 5, 9, and every 8 week intervals thereafter until study completion, an average of 12 months
Primary	HIV-1 seroincidence rate in a cohort of high-risk TGW	Incidence of HIV-1 infection in subject's post-study entry will be assessed by determining number of subjects who become infected with HIV-1 post-screening and after study entry including Day 1 and subsequent observation visits. Confirmatory HIV serology test will be performed at seroconversion visit.	Baseline, Day 1, Weeks 5, 9, and every 8 week intervals thereafter until study completion, an average of 12 months
Secondary	Number of subjects diagnosed with gonorrhea, chlamydia, and syphilis post screening	Infections like gonorrhea, chlamydia, and syphilis will be assessed by toluidine red unheated serum test (TRUST) for syphilis and STI testing.	Day 1, Week 9, and every 16 weeks interval thereafter until study completion, an average of 12 months
Secondary	Number of subjects with demographic factors	Demographic factors associated with HIV seroconversion and STI acquisition will be assessed by computer-assisted self-interview (CASI).	Day 1, Week 9, and every 8 weeks interval thereafter until study completion, an average of 12 months
Secondary	Number of subjects enrolled and retained in to the study	Measures will be utilized to effectively engage and retain the subjects in the study. Retention strategies to be studied may include community engagement, interpersonal relationship building and reduction of external barriers.	Day 1, Weeks 5, 9, and every 8 or 16 weeks interval thereafter until study completion, an average of 12 months

External Links

•   Results for study 206897 can be found on the ViiV Clinical Study Register.